...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 Single Agent Trial Status

IMO, I think a deal  for both Zenith  and RVX has been in the works for over a year and was very close last November but negotiations may have been stalled,  maybe a year later with more clinical data from Zenith and where we are with the  betonmace trial 4 DSMB safety clearance and a good chance of a positive futility analysis that a deal of any sort could happen at anytime.  That being said the only thing we do know is a LOI for a regional license deal from the Aug 28 NR.  

 

My guess is CVR for both companies  which DM had mentioned years ago as very good option for both parties ,  

6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM
Share
New Message
Please login to post a reply